Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02397967
Other study ID # 08 113 01
Secondary ID
Status Completed
Phase N/A
First received March 13, 2015
Last updated March 25, 2015
Start date June 2009
Est. completion date April 2014

Study information

Verified date March 2015
Source University Hospital, Toulouse
Contact n/a
Is FDA regulated No
Health authority France: Ministry of Health
Study type Interventional

Clinical Trial Summary

A national, multicenter, randomized, transverse clinical trial, estimating the existence of phonological deficits in children with NF1 children compared with control children without NF1 with the same reading level.


Description:

To determine the phonological and visio -spatial performances at the NF1 children.


Recruitment information / eligibility

Status Completed
Enrollment 181
Est. completion date April 2014
Est. primary completion date April 2014
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 8 Years to 12 Years
Eligibility Inclusion Criteria:

- Age included between 8 and 12 years

- Child presenting a type 1 neurofibromatosis according to 2 criteria in the following criteria list :

- At least 6 café au lait spots

- 2 or more neurofibromas or 1 plexiform neurofibroma

- axillary or inguinal freckling

- 1 optic nerf glioma

- 2 or more Lisch nodules

- 1 osseous lesion as sphenoid dysplasia or thinning of the long bone cortex with or without pseudoarthrosis

- 1 A first degree relative (parent, sibling, or offspring) with NF1 by the above criteria

- Membership in a national insurance

- Consent of the child and the parents

Exclusion Criteria:

- Mental retardation (QI T < 70)

- Treated or untreated epilepsy

- Visual deficit (visual Acuteness < 4/10

- Presence of a symptomatic optic glioma

- Presence of a brain tumor.

Study Design

Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Screening


Intervention

Other:
Neuropsychological assessments
Neuropsychological assessments: Intelligence Quotient (WISC-IV) Reading tests (reading accuracy, reading speed, reading comprehension and strategy): Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)

Locations

Country Name City State
France Hopital femme-mére-enfant, Hospices civils de lyon Lyon
France Hôpital Gui de Chauliac Montpellier
France CHU Hôtel-Dieu, Clinic of Dermatology Nantes
France AP-HP Hopital Armand Trousseau Paris
France Hôpital des Enfants Toulouse
France Hopital Gatien de Clocheville Tours

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Toulouse

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phonological deficits evaluated by the metaphonological capabilities including a subtraction test and phonemic Acronym test and memory capacity with phonological phonological memory test. Evaluate whether there is a specificity of phonological deficits in children with NF1 compared with a population of children with the same age and same reading level, taking into account the intellectual level. 24 hours No
Secondary Visual-perceptual performance established from three tests: Test of Identical Forms (Thurstone), Judgment Test of orientation Lines (Benton) and global and partial deferral Tasks (S Valdois). Studying the correlations between phonological deficits and visio-spatial and literacy skills. 24 hours No
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03190915 - Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia Phase 2
Completed NCT03326388 - Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours Phase 1/Phase 2
Completed NCT00026780 - Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
Active, not recruiting NCT01362803 - AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors Phase 1/Phase 2
Active, not recruiting NCT01218139 - Analysis of Peripheral Nerve Sheath Tumors (PNSTs) in Neurofibromatosis Type 1 (NF1) Patients N/A
Recruiting NCT05149469 - Molecular Aspects of Preimplantation Genetic Diagnosis for NF1
Not yet recruiting NCT02505412 - Subtle Myocardial Deformation Abnormalities in Asymptomatic Nf-1 Patients N/A
Terminated NCT02256124 - Effect of Lamotrigine on Cognition in NF1 Phase 2/Phase 3
Completed NCT01707836 - Neurofibromatosis Type 1 Brain Tumor Genetic Risk N/A
Active, not recruiting NCT01218152 - Microarray CGH Analysis of Circulating Tumoral Plasma DNA in NF1 Patients With MPNSTs N/A
Recruiting NCT03975829 - Pediatric Long-Term Follow-up and Rollover Study Phase 4
Recruiting NCT05186870 - Reliability of Functional Outcome Measures in Neurofibromatosis 1: Test- Retest
Active, not recruiting NCT03231306 - Phase II Study of Binimetinib in Children and Adults With NF1 Plexiform Neurofibromas Phase 2
Withdrawn NCT03332030 - Stem Cells in NF1 Patients With Tumors of the Central Nervous System
Recruiting NCT02964884 - Interventions for Reading Disabilities in NF1 Phase 2
Recruiting NCT05388370 - PASS of Paediatric Patients Initiating Selumetinib
Recruiting NCT02777775 - Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Completed NCT02944032 - Efficacy of Computerized Cognitive Training and Stimulant Medication in Neurofibromatosis Type 1 N/A
Completed NCT01851135 - Neuropsychological Impairment and Quality of Life in Neurofibromatosis Type 1 N/A
Completed NCT01410006 - Neurofibromatosis Type 1 Patient Registry N/A